AnPac Bio-Medical Science Co., Ltd. announced that effective August 2, 2022, the board of directors appointed Yuyang Cui as Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presenting potential business opportunities to the Company and the Board as well as (ii) the capital markets strategy and related activities for AnPac Bio. Chris Chang Yu has since been re-designated as the Co-Chief Executive Officer of the Company, with primary responsibilities for the general operations and all related businesses except for the duties that are outlined for Mr. Cui.

As previously reported, on July 14, 2022, written resolutions were passed by a majority of the votes of all shareholders entitled to vote at a general meeting authorizing, among others, the removal of Aidong Chen as Co-Chairman of the Board and Co-Chief Executive Officer of the Company; and the re-designation of Chris Chang Yu as Chief Executive Officer of the Company and Chairman of the Board.